| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8454666 | Lung Cancer | 2016 | 6 Pages |
Abstract
Following crizotinib discontinuation, many patients received no further antineoplastic therapy, and OS was poor among patients who did not receive a second-generation ALK inhibitor. Recently available second-generation ALK inhibitors may provide important treatment options for ALK+ NSCLC patients.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Jacques Cadranel, Keunchil Park, Oscar Arrieta, Miklos Pless, Edmond Bendaly, Dony Patel, Medha Sasane, Adam Nosal, Elyse Swallow, Philip Galebach, Andrew Kageleiry, Karen Stein, Ravi Degun, Jie Zhang,